| 45th week of 2009 patent applcation highlights part 38 |
| Patent application number | Title | Published |
|---|
| 20090275603 | NF- kB Inhibitors And Uses Thereof - A new class of imidazolines as 4-position esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma, etc.), antibacterial agents, and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-κB as well as potent activity against the Gram (+) bacterium. The compositions are also useful for treating autoimmune diseases and for inhibiting rejection of organ and tissue transplants. | 2009-11-05 |
| 20090275604 | M3 Muscarinic Acetylcholine Receptor Antagonists - Muscarinic Acetylcholine receptor antagonists and methods of using them are provided. | 2009-11-05 |
| 20090275605 | 3,11 b-cis-Dihydrotetrabenazine for the Treatment of a Proliferative Disease or an Inflammatory Disease - The invention provides the use of a compound for the manufacture of a medicament for the prophylaxis or treatment of a proliferative disease or an inflammatory disease, the compound being 3,11b-cis-dihydrotetrabenazine or a pharmaceutically acceptable salt thereof. | 2009-11-05 |
| 20090275606 | Heterocyclic Compounds as MEK Inhibitors - The present invention relates to compounds of formula I | 2009-11-05 |
| 20090275607 | Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof - A kind of tetrahydro isoquinoline derivatives (I), their preparation methods, medicine compositions and medicinal uses thereof, especially their uses as κ-opioid receptor excitant in pain relieving, which belongs to the medicine chemistry. The substituents R | 2009-11-05 |
| 20090275608 | Methods of diagnosing and treating parp-mediated diseases - Disclosed are methods of identifying a disease treatable with modulators of differentially expressed genes in a disease, including at least PARP modulators, by identifying the level of expression of differentially expressed genes, including at least PARP, in a plurality of samples from a population, making a decision regarding identifying the disease treatable by modulators to the differentially expressed genes wherein the decision is made based on the level of expression of the differentially expressed genes. The method can further comprise treating the disease in a subject population with modulators of identified differentially expressed genes. The methods relate to identifying up-regulated expression of identified differentially-expressed genes in a disease and making a decision regarding the treatment of the disease. The level of expression of the differentially expressed genes in a disease can also help in determining the efficacy of the treatment with modulators to the differentially expressed genes. | 2009-11-05 |
| 20090275609 | Carboxamide Compounds and Methods for Using The Same - Disclosed are carboxamide compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure | 2009-11-05 |
| 20090275610 | TRICYCLIC OPIOID MODULATORS - The invention is directed to compounds of Formula (I) useful as delta and mu opioid receptor modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described. | 2009-11-05 |
| 20090275611 | Compounds Which Modulate The CB2 Receptor - Compounds are provided which bind to and are agonist, antagonists or inverse agonists of the CB2 receptor, the compounds having the general formula (I) wherein R | 2009-11-05 |
| 20090275612 | Compound With Antimalarial Activity And Antimalarial Drug Containing The Same As Active Ingredient - Compounds with high antimalarial activity; and antimalarial drugs containing the same as an active ingredient. There are provided compounds with antimalarial activity represented by the chemical formula: (wherein R | 2009-11-05 |
| 20090275613 | INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 - The present invention discloses novel compounds of Formula I: (I) possessing 11β-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11β-HSD type 1 activity. | 2009-11-05 |
| 20090275614 | Methylphenidate Derivatives and Uses of Them - The present invention provides methods of using compounds of formula I: | 2009-11-05 |
| 20090275615 | Method of treating thermoregulatory disfunction with paroxetine - The present invention relates to a method for treating a patient suffering from a thermoregulatory dysfunction, especially hot flashes and flushes associated with hormonal changes due to naturally occurring menopause (whether male or female) or due to chemically or surgically induced menopause. The method is also applicable to treating the hot flashes, hot flushes, or night sweats associated with disease states that disrupt normal hormonal regulation of body temperature. | 2009-11-05 |
| 20090275616 | STRAIGHTFORWARD ENTRY TO 7-AZABICYCLO[2.2.1]HEPTANE-1-CARBONITRILES AND SUBSEQUENT SYNTHESIS OF EPIBATIDINE ANALOGUES - The present invention relates to a group of substituted-7-azabicyclo-[2.2.1]heptyl derivatives with biological activity. The present invention also relates to synthetic methods for producing said substituted-7-azabicyclo-[2.2.1]heptyl derivatives. The present invention also relates to certain intermediates for producing such substituted-7-azabicyclo-[2.2.1]heptyl derivatives, as well as a synthetic method for producing such intermediates. The present invention also relates to pharmaceutical compositions comprising such substituted-7-azabicyclo-[2.2.1]heptyl derivatives, as well as their use as medicaments for the treatment of diseases mediated by a Nicotinic Acetylcholine Receptor or a receptor being a member of the Neurotransmitter-gated Ion Channel Superfamily, such as pain, Alzheimer's disease, Parkinson's disease, schizophrenia, epilepsy and nicotine addiction. | 2009-11-05 |
| 20090275617 | Aryl-Substituted Nitrogen-Containing Heterocyclic Compounds - Disclosed is an aryl-substituted nitrogen-containing heterocyclic compound represented by the formula (I) below or a pharmaceutically acceptable salt thereof. This compound serves as nociceptin receptor antagonist and is useful as a pharmaceutical agent for treating diseases associated with a nociceptin receptor. (I) | 2009-11-05 |
| 20090275618 | 1, 5-DIPHENYL-3-BENZYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CB1 RECEPTOR MODULATORS - Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB | 2009-11-05 |
| 20090275619 | Amide Substituted Indazole and Benzotriazole Derivatives as Poly(ADP-Ribose)Polymerase (PARP) Inhibitors - The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment. | 2009-11-05 |
| 20090275620 | SUBSTITUTED 5- PHENYLAMINO- 1, 3, 4-OXADIAZOL-2-YLCARBONYLAMINO-4-PHENOXY-CYCLOHEXANE CARBOXYLIC ACID AS INHIBITORS OF ACETYL COENZYME A DIACYLGLYCEROL ACYLTRANSFERASE - Compounds of formula (I), or salts thereof, which inhibit acetyl CoA (acetyl coenzyme A):diacylglycerol acyltransferase (DGAT1) activity are provided, | 2009-11-05 |
| 20090275621 | 1, 3, 4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF - The present invention is directed to 1,3,4-oxadiazalones, compounds of formula I and their pharmaceutically acceptable salts stereoisomers, tautomers, or solvates thereof. Novel compounds include those of formula I, in which radicals are as defined herein. | 2009-11-05 |
| 20090275622 | NIZATIDINE FORMULATIONS - Pharmaceutical formulations comprising nizatidine or salts thereof. Further the invention relates to liquid pharmaceutical formulations comprising nizatidine or salts thereof. | 2009-11-05 |
| 20090275623 | ALPHA-AMINO ACID DERIVATIVES AND MEDICAMENTS CONTAINING THE SAME AS AN ACTIVE INGREDIENT - The present invention provides novel α-amino acid derivatives of formula (1): | 2009-11-05 |
| 20090275624 | INHIBITORS OF CDC PHOSPHATASES - A subject of the present invention is novel compounds comprising 2 or 3 benzothiazole-4,7-dione- or benzooxazole-4,7-dione-type units, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer. | 2009-11-05 |
| 20090275625 | NOVEL THIAZOLIDIN 4-ONE DERIVATIVES - The invention relates to pharmaceutical compositions containing at least one thiazolidin-4-one derivative to prevent or treat disorders associated with an activated immune system. Furthermore, the invention relates to novel thiazolidin-4-one derivatives notably for use as pharmaceutically active compounds. Said compounds particularly act also as immunosuppressive agents. | 2009-11-05 |
| 20090275626 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROGENIC PAIN - The purpose of the present invention is to provide agents useful for the prevention or treatment of a neuropathic pain. That is, the present invention provides agents for the prevention or treatment of neuropathic pain such as painful diabetic neuropathy, postherpetic neuralgia, trigeminal neuralgia, or postoperative or posttraumatic chronic pain or the like, which comprises a β | 2009-11-05 |
| 20090275627 | ALPHA2B AND ALPHA2C AGONISTS - Described herein are compounds that can be useful as bioactive agents. More specifically, the compounds described herein can be useful as both α | 2009-11-05 |
| 20090275628 | Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments - The present invention relates to substituted spiro compounds, to processes for preparing them, to medicaments comprising these compounds and to the use of these compounds for producing medicaments. | 2009-11-05 |
| 20090275629 | THERAPY FOR THE TREATMENT OF DISEASE - Disclosed herein are pharmaceutical compositions comprising various combinations of an antimuscarinic or an anticholinergic agent, a compound that causes stimulation of salivary glands, and a compound that relieves constipation. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition. | 2009-11-05 |
| 20090275630 | COSMETIC COMPOSITION COMPRISING AN IMIDOPERCARBOXYLIC ACID DERIVATIVE AND A N-ACYLATED AMINO ACID ESTER - Composition containing, in a physiologically acceptable medium, at least one imidopercarboxylic acid compound and at least one N-acylated amino acid ester of formula (A) as described herein. | 2009-11-05 |
| 20090275631 | THERAPEUTIC ANTISENSE OLIGONUCLEOTIDE COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5′-GCCCAAGCTGGCATCCGTCA-3′, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal. | 2009-11-05 |
| 20090275632 | Methods of diagnosis and treatment - A method of diagnosing a disease in which an miRNA is expressed at a lower level comprises, in a test sample obtained from a subject, determining the methylation status of at least one gene encoding the miRNA in the sample, wherein the presence of methylation is indicative of the presence of the disease. Methylation of the gene causes a down regulation in expression which may also be monitored. Related methods and kits are also described based upon methylation of miRNA encoding genes. The primary miRNA of interest is 124a miRNA. | 2009-11-05 |
| 20090275633 | Novel Tumour Suppressor - A method of diagnosing cancer includes the steps of, in a sample obtained from a subject, determining the level or activity of HDAC2. A reduced level or activity of HDAC2 is indicative of cancer. HDAC2 protein expression is preferably determined. Indirect determination of HDAC2 expression is also possible, preferably by looking at the expression of genes selected from NCOA4, CTSB, TBCD, PPP2R4 and CORO1C. Methods for predicting the probability of successful treatment of cancer using a hydroxamic acid based HDAC inhibitor and for selecting suitable cancer treatment regimens can also be based upon determining the level or activity of HDAC2. Methods of treatment of cancer may be based upon use of carboxylic acid based HDAC inhibitors or by reconstituting HDAC2 activity. | 2009-11-05 |
| 20090275634 | ANTISENSE OLIGONUCLEOTIDES AGAINST ACETYLCHOLINESTERASE FOR TREATING INFLAMMATORY DISEASES - The present invention relates to novel uses of antisense oligonucleotides targeted to the coding region of acetylcholinesterase (AChE) for treating inflammatory disorders other than inflammatory disorders of the central nervous system or the peripheral nervous system innervating voluntary muscles. More particularly, the present invention relates to uses of antisense oligodexoynucleotides targeted to AChE mRNA for treating inflammatory disease of the gastrointestinal tract including inflammatory bowel disease. | 2009-11-05 |
| 20090275635 | SCREENING METHOD - The invention provides a method of modulating Wnt signalling comprising modulating Trabid activity. Preferably modulating Trabid activity comprises inhibiting; Trabid activity. The invention also provides a method of reducing TCF transcription, said method comprising reducing Trabid activity. A method for identifying a-modulator of Trabid said method comprising; providing a Trabid substrate comprising a detectable moiety coupled to a tag moiety by ubiquitin; immobilising first and second portions of said substrate; adding a candidate modulator to the first said portion; contacting first and second portions with Trabid; incubating to allow Trabid action, assaying cleavage of ubiquitin by separation of tag from detectable moiety, wherein separation of an amount of detectable moiety from said first portion which is different from the amount of detectable moiety separated from said second portion identifies said candidate as a modulator of Trabid. The invention provides uses of Trabid and of Trabid inhibitors as-medicaments. | 2009-11-05 |
| 20090275636 | PICORNAVIRUS AND USES THEREOF - The invention is directed to a a clade of newly isolated and identified picornaviruses associated with respiratory infection, and isolated nucleic acids sequences and peptides thereof. The invention also relates to antibodies against antigens derived from the picornavirus. The invention also relates to iRNAs which target nucleic acid sequences of the picornavirus. The invention is related to methods for detecting the presence or absence of picornavirus in a subject. The invention is also related to immunogenic compositions for inducing an immune response against picornavirus in a subject. | 2009-11-05 |
| 20090275637 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS - The present invention provides compositions and methods for binding and/or modulating enzymatic activity of human protein tyrosine phosphatases such as PTP1B. Additionally, the invention provides methods of identifying and using such nucleic acid ligands. | 2009-11-05 |
| 20090275638 | Compositions and Methods for Inhibiting Expression of XBP-1 Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting X-Box Protein 1 (XBP-1), and methods of using the dsRNA to inhibit expression of XBP-1. | 2009-11-05 |
| 20090275639 | USP47 INHIBTORS AND METHODS TO INDUCE APOPTOSIS - The present invention relates to USP47 (ubiquitin specific protease 47) inhibitors and methods for inducing apoptosis or cell death in a target cell. In certain embodiments, the invention relates to methods and kits to screen for related agents that induce apoptosis. Additionally, the invention relates to assays for screening compounds capable of acting as USP47 inhibitors. | 2009-11-05 |
| 20090275640 | siRNA targeting inner centromere protein antigens (INCENP) - Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for INCENP. | 2009-11-05 |
| 20090275641 | RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders - RNA interference is provided for inhibition of Rho kinase mRNA expression for treating patients with ocular disorders, particularly for treating intraocular pressure, ocular hypertension and glaucoma. Rho kinase mRNA targets include mRNA for ROCK1 and ROCK2. | 2009-11-05 |
| 20090275642 | DNA COMPOSITION FOR ELICITING AN IMMUNE RESPONSE AGAINST TUMOR-ASSOCIATED MACROPHAGES - The present invention provides a DNA composition comprising a DNA minigene construct that encodes for a polypeptide comprising a plurality of immunogenic fragments of a cysteine endopeptidase that is expressed in tumor-associated cells. The immunogenic fragments are joined together serially by a linker peptide between each successive fragment in the polypeptide. The polypeptide is capable of eliciting an immune response against the tumor-associated cells, is expressible in immune cells, and is incorporated in a pharmaceutically acceptable carrier. | 2009-11-05 |
| 20090275643 | Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis - The invention provides a method for inhibiting ocular neovascularization in a patient. The method comprises administering to a patient an ocular neovascularization inhibiting amount of a water-soluble polypeptide selected from the group consisting of SEQ ID NO: 12, SEQ ID NO: 7, and an ocular neovascularization inhibiting fragment thereof, which includes at least one of amino acid residue signature sequences HVGH (SEQ ID NO:10) and KMSAS (SEQ ID NO:11). A method for assaying the angiogenesis inhibiting activity of a composition is also provided | 2009-11-05 |
| 20090275644 | Novel adaptor protein that binds to mammalian toll-like receptor 3 and gene thereof - A novel adaptor protein and its gene are provided. The novel adaptor protein has a property of binding to mammalian Toll-like receptor 3, which controls type I interferon production that is effective for prevention/treatment of viral infectious disease such as hepatitis B, hepatitis C, and the like, treatment of tumors, and the other purposes. Novel adaptor protein TICAM-1, which has an amino acid sequence set forth in SEQ ID NO: 2 or 4, specifically binds to the mammalian Toll-like receptor 3 and induces production of type I interferon. A mutant of the adaptor protein TICAM-1 has similar properties, provided that it has TIR domain (an amino acid sequence ranging from 394-position to 532-position in the amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence ranging 396-position to 534-position in the amino acid sequence set forth in SEQ ID NO: 4). The gene is a gene encoding the adaptor protein TICAM-1. | 2009-11-05 |
| 20090275645 | METHOD TO INDUCE NEOVASCULAR FORMATION AND TISSUE REGENERATION - The present invention relates, e.g., to a method for inducing arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or for inducing mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte, comprising administering to a cell or tissue in need thereof a dose of a polynucleotide that encodes a vascular endothelial growth factor (VEGF), or that encodes a polypeptide comprising an active site of the VEGF. The coding sequence is operably linked to an expression control sequence; and the dose is sufficient to induce arteriogenesis, lymphangiogenesis, vasculogenesis, or cardiomyogenesis, and/or to induce mitosis or proliferation of a smooth muscle cell, a skeletal muscle cell, or a cardiomyocyte. In preferred embodiments of the invention, the method is a method of tissue regeneration, particularly of cardiomyogenesis; and the polynucleotide (or a polypeptide encoded by such a polynucleotide) is administered into the myocardium. | 2009-11-05 |
| 20090275646 | THERAPEUTIC COMPOUNDS - Compounds having a structure | 2009-11-05 |
| 20090275647 | TAXANE DERIVATIVE COMPOSITION - A stable, absolutely ethanol free composition of docetaxel that prevents alcoholic intoxication or anaphylactic shock. The composition can be in the form of a stable injectable composition that includes a taxane derivative, wherein the composition includes a mixture of docetaxel, one or more stabilizer, one or more surfactant, or more co-solvent and water for injection wherein the composition is absolutely free of ethanol. | 2009-11-05 |
| 20090275648 | MACROCYCLIC GHRELIN RECEPTOR ANTAGONISTS AND INVERSE AGONISTS AND METHODS OF USING THE SAME - The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and/or variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as antagonists or inverse agonists of the ghrelin receptor and as medicaments for treatment and prevention of a range of medical conditions including, but not limited to, metabolic and/or endocrine disorders, cardiovascular disorders, obesity and obesity-associated disorders, gastrointestinal disorders, genetic disorders, hyperproliferative disorders and inflammatory disorders. | 2009-11-05 |
| 20090275649 | Compositions And Methods For Identifying Modulars Of TRPV2 - It has now been discovered that certain cannabinoids specifically activate TRPV2 channel activity. Based on the discovery, novel compositions and methods for screening, identifying and characterizing compounds that increase or decrease the biological activity of a TRPV2. | 2009-11-05 |
| 20090275650 | 3-Acyl coumarins, thiochromones and quinolones and therapeutic uses thereof - Compounds of Formula I: | 2009-11-05 |
| 20090275651 | Alcanoic Acid Amides Substituted by Saturated O-Heterocycles - Compounds of the general formula (formula I) in which the meanings of the substituents R1 to R6 are as indicated in claim | 2009-11-05 |
| 20090275652 | BIOFILM FORMATION INHIBITOR COMPOSITION - A drug and a composition for inhibiting biofilm formation are provided. A biofilm formation inhibitor composition containing the following component (A): (A) at least one or more selected from compounds represented by Formula (1) to Formula (4): wherein R | 2009-11-05 |
| 20090275653 | POLYMORPHIC FORMS OF LADOSTIGIL TARTRATE - The invention provides for solid state chemistry of ladostigil tartrate, particularly polymorphic forms of ladostigil tartrate, and processes for the preparation thereof. | 2009-11-05 |
| 20090275654 | Pharmaceutical Gallium Compositions and Methods - The present invention provides novel pharmaceutical gallium compositions, as well as methods for their preparation and methods for treating conditions and diseases such as cancer, hypercalcemia, osteoporosis, osteopenia, and Paget's disease. | 2009-11-05 |
| 20090275655 | Pharmaceutical Gallium Compositions and Methods - The present invention provides novel pharmaceutical gallium compositions, as well as methods for their preparation and methods for treating conditions and diseases such as cancer, hypercalcemia, osteoporosis, osteopenia, Paget's disease, and infections. | 2009-11-05 |
| 20090275656 | Medicinal Compositions of Salts, Chelates and/or Free Acids of Alpha Hydroxyl Organic Acids and Related Processes and Methods - Processes are described for the production of an isolated medicinal composition for administration to mammals which comprises an effective amount of a free acid, salt or chelate of at least one naturally occurring form of an alpha hydroxyl organic acid comprising combining at least one naturally occurring form of an alpha hydroxy organic acid with an amount of base in an aqueous solution, wherein a total content of alpha hydroxyl organic acids amounts to between about 0.5% and about 35% w/w of the solution, for a time to hydrolyse substantially all forms of alpha hydroxyl organic acids present, neutralizing the solution to a pH between about 6.9 and about 7.6 to yield a free acid, salt or chelate of free acids of substantially all naturally occurring forms of alpha hydroxyl organic acids, and optionally lyophilizing the solution to produce an isolated medicinal composition. Compositions produced by these processes are disclosed and claimed. Method are described of enhancing DNA repair, enhancing an immune response, controlling inflammation, or inhibiting the progress of a tumor, comprising administering an effective amount of a composition produced by the processes described herein. | 2009-11-05 |
| 20090275657 | Fatty acid antimicrobial - The novel antimicrobial composition is disclosed including from about 60 to 95% of a lipophilic polar solvent such as propylene glycol, ethylene glycol, or isopropanol and from about 0.5 to 5% of a mixture of C | 2009-11-05 |
| 20090275658 | Method for Producing a Raw Oil from Mixtures of Micro-Organisms and Plants, Oil Produced According to Said Method and Specific Uses of the Thus Produced Oil and, Optionally, Additional Refined Oil - The invention relates to a method for producing a raw oil from micro-organisms and plants, oil produced according to said method and specific uses of the thus produced oil and, optionally, additional refined oil in foodstuffs, in food supplements, or in cosmetic or pharmaceutical compositions. | 2009-11-05 |
| 20090275659 | Phenyl acetic acid derivatives as inflammation modulators - Compounds, pharmaceutical compositions and methods are provided that are useful in the treatment of inflammatory and immune-related diseases and conditions. In particular, the invention provides compounds which modulate the function and/or expression of proteins involved in atopic diseases, inflammatory conditions and cancer. The subject compounds are carboxylic acid derivatives. | 2009-11-05 |
| 20090275660 | STABLE PARENTERAL FORMULATIONS OF TIGECYCLINE - The present invention relates to stable parenteral formulations of tigecycline and process of preparation thereof, wherein the formulation comprises of an edetate, a pH modifying agent or an antioxidant, such that the formulation remains stable for at least 45 hours. | 2009-11-05 |
| 20090275661 | PREPARATION OF THE FORMAURINDICARBOXYLIC ACID BASE AND ITS DERIVATIONS AND USE - A pharmaceutical composition comprising at least 0.1 μmol of formaurindicarboxylic acid or its derivatives in 1 kg of pharmaceutically acceptable carrier. The pharmaceutical composition of claim | 2009-11-05 |
| 20090275662 | Injectable veterinary composition - Injectable veterinary composition comprising a fluorinated chloramphenicol or thiamphenicol derivative and a solvent system comprising an ether of 1,2-ethanediol oligo- or polymers, and a pyrrolidone solvent. | 2009-11-05 |
| 20090275663 | Method for Producing a Disinfecting Agent - The invention relates to medicine, in particular to sanitary and hygiene, more specifically to methods for producing a disinfecting agent for decontaminating different types of water, including drinking water. The inventive disinfecting agent producing method by dissolving quaternary ammonium compounds in water in the presence of an active additive in the form of guanidines, consists in preparing an aqueous 1-15% guanidine solution by permanently agitating it at a temperature ranging from 30 to 90° C., in cooling the solution accompanied with a precipitation control, when the precipitation process is over, in filtering the solution by using a filter whose cell size ranges from 10 to 1 mkm and in adding the quaternary ammonium compounds into the solution in such away that the concentration thereof in said solution is equal to 0.1-3%. | 2009-11-05 |
| 20090275664 | NOVEL POLYAMINE ANALOG CONJUGATES AND QUINONE CONJUGATES AS THERAPIES FOR CANCERS AND PROSTATE DISEASES - Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of prostate diseases are also provided. | 2009-11-05 |
| 20090275665 | Enhanced biological potential of greater than 99% pure form of 1, 7-bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione over corresponding 95% pure form-therapeutic and agricultural applications thereof - Disclosed are novel and enhanced anti-fungal properties of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione in comparison with the corresponding 95% pure form, said greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione being devoid of 5-Hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-3-heptanone and 3,5-Dihydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-heptane. The inventors disclose the uses of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione as anti-fungal agents capable of inhibiting superficial and cutaneous mycoses in humans and treatment methods thereof. Also disclosed is the enhanced potential of greater than 99% pure form of 1,7-Bis(4-hydroxy-3-methoxyphenyl)-3,5-heptanedione as compared to the corresponding 95% pure form against bacterial and fungal phytopathogens and applications thereof in agriculture. | 2009-11-05 |
| 20090275666 | CONDENSATION PRODUCTS, METHOD FOR THEIR PRODUCTION AND USE THEREOF IN MEDICAMENTS, AS DISINFECTANTS OR AS A TANNIN - The invention relates to a condensation product obtainable by reaction of
| 2009-11-05 |
| 20090275667 | USE OF ALLICIN AS PRESERVATIVE, AS DISINFECTANT, AS ANTIMICROBIAL OR AS BIOCIDAL AGENT - The present invention provides the use of allicin in (i) the treatment of leishmanimis; (b) as a disinfectant or biocidal treatment of aquatic species; (iii) as an antimicrobial agent for animal feed; (iv) as a preservative agent in foodstuffs; (v) as a water disinfectant or biocide; (vi) as an antiparasitic treatment or antibacterial treatment for bees (apis); or (vii) in the preparation of a medicament for the treatment of Glycopeptide Intermediate Resistant | 2009-11-05 |
| 20090275668 | Sprayable Gel-Type Skin/Mucosa-Adhesive Preparation and Administration System Using the Preparation - The present invention provides a sprayable gel-type skin/mucosa-adhesive preparation comprising a gel formulation which contains an active pharmaceutical ingredient in a gel base material comprising a skin/mucosa-adhesive agent and an administration system comprising the preparation. | 2009-11-05 |
| 20090275669 | Flavor and fragrance composition - A flavor and fragrance composition with a cooling sensation effect comprising 1-(2-hydroxy-4-methylcyclohexyl)ethanone represented by the formula (1). The flavor and fragrance composition is added to a beverage or food product, a fragrance or cosmetic product, a daily utensil product, an oral composition, or a pharmaceutical product in the range of 0.0001 to 20% by weight to the total weight of the flavor and fragrance composition added. | 2009-11-05 |
| 20090275670 | DOG PHEROMONE FORMULATION AND DELIVERY SYSTEM - The present invention is directed to a dog behavioral control system comprising a low melting point polymer or copolymer, an unsaturated long chain fatty alcohol, and a dog-appeasing pheromone to produce a solid slow release generator of the pheromone. The system is useful for making animal collars and the like. | 2009-11-05 |
| 20090275671 | TWO COMPONENT BONE CEMENT COMPOSITION FOR VERTEBROPLASTY - The invention is directed to an intrinsically radio-opaque two component bone cement, comprising a first component which contains at least one acrylate monomer and a second component which contains at least one initiator for the polymerisation of said acrylate monomer, wherein the at least one iodine containing radio-opacity providing polymer is present in at least one of the two components and wherein the cement, when mixed into a slurry has a viscosity, which is sufficiently low to allow injection of the cement slurry through a needle with a diameter in the range of 10-15 G used in percutaneous vertebroplasty. | 2009-11-05 |
| 20090275672 | Sustained-Release Tablet Production Process - A process is provided for efficiently producing sustained-release tablets having superior sustained-release properties capable of inhibiting the initial elution of a drug and allowing the drug to be completely eluted after a prescribed amount of time has elapsed. A process for producing sustained-release tablets comprising: dry granulating a mixture composed of a hydroxyalkyl cellulose (A) having a viscosity of 1 to 50 mPa·s in a 2% by mass aqueous solution at 20° C., a hydroxyalkyl cellulose (B) having a viscosity of 100 mPa·s or more in a 2% by mass aqueous solution at 20° C., an active ingredient and an additive, and forming the resulting granules into tablets. | 2009-11-05 |
| 20090275673 | Benzocyclobutene based polymer formulations and methods for processing such formulations in oxidative environments - The use of hindered phenol containing anti-oxidants enable arylcyclobutene-based formulations to be cured in oxygen containing environments such as air without unacceptable degradation in key properties of dielectric constant, water uptake, or transmittance. | 2009-11-05 |
| 20090275674 | UV/EB Curable Biobased Coating for Flooring Application - A radiation curable biobased coating, such as a UV/EB curable biobased coating, for flooring applications includes a biobased component comprising renewable and/or biobased materials. The biobased component is selected from the group consisting of a biobased resin, a biobased polyol acrylate, or a biobased polyol. The biobased component is blended with a coating formula. The coating formula includes at least one initiator. The radiation curable biobased coating contains at least about 5% weight of renewable materials or biobased content. | 2009-11-05 |
| 20090275675 | RUBBER COMPOSITION FOR TREAD AND PNEUMATIC TIRE USING THE SAME - A method of compounding a modified, epoxidized natural rubber for use as a tire tread which includes the steps of modifying an epoxidized natural rubber containing a ring-opened epoxy group, compounding the modified, epoxidized natural rubber with another rubber, to form a rubber compound, together with silica and/or carbon black to form a rubber composition, and forming the rubber composition into a tire tread. | 2009-11-05 |
| 20090275676 | Process for Producing Particulate Resin - A process for particulate-resin production from an aqueous solution containing resin particles by recovering the particulate resin from the solution. In recovering the particulate resin from the aqueous solution, a lubricant is added in an amount of 0.05-5 parts by weight per 100 parts by weight of the resin ingredient contained in the particulate resin and a dispersant is added in an amount 0.1 to 1 time by weight the amount of the lubricant. Thus, a particulate resin excellent in transparency and blocking resistance can be obtained. In particular, a particulate isobutyrene block copolymer resin can be stably produced. | 2009-11-05 |
| 20090275677 | COATING COMPOSITION - An aqueous coating composition comprising a mixture of recycled rubber particles, and particles at least one of glass or plastic particles, graphite particles and fluorinated resin particles such as polytetrafluoroethytlene and a suspension agent or resin. Various embodiments are useful for coating suitable for highways and parking lots, roofs or swimming pools and metal surfaces and for “rubberizing” marine and other manufactured products. | 2009-11-05 |
| 20090275678 | THERMOPLASTIC RESIN COMPOSITION AND MOLDED ARTICLE THEREOF - A thermoplastic resin composition and a molded article thereof, respectively excellent in flowability and mechanical properties, and, in a preferred mode, also excellent in low warping property, laser transmittance and laser weldability, is obtained by mixing (B) 0.1 to 4 parts by weight of a polyfunctional compound having three or more functional groups, in which at least one of the terminal structures having the functional groups is a structure containing alkylene oxide units, with (A) 100 parts by weight of a thermoplastic resin, and further provides a molded particle thereof. It is preferred that the (A) thermoplastic resin is one or more selected from a polyester resin and polycarbonate resin. | 2009-11-05 |
| 20090275679 | System and method for the pre-treatment of rubber-modified asphalt cement, and emulsions thereof - This invention encompasses asphalt cement emulsions, as well as methods for preparing a pre-treated rubber-modified asphalt cement emulsions and methods for coating industrial surfaces using asphalt cement emulsions. | 2009-11-05 |
| 20090275680 | HIGHLY FUNCTIONAL, HIGHLY BRANCHED OR HYPERBRANCHED POLYESTERS, THE PRODUCTION THEREOF AND THE USE OF THE SAME - High-functionality highly branched or hyperbranched polyesters based on di-, tri- or polycarboxylic acids and di-, tri- or polyols, processes for preparing them, and their use. | 2009-11-05 |
| 20090275681 | PROCESS FOR PREPARING AN AQUEOUS POLYMER DISPERSION - Process for preparing an aqueous polymer dispersion using alkenes of 4 to 40 carbon atoms. | 2009-11-05 |
| 20090275682 | Resin Composition Excellent in Flame Retardance - The present invention relates to a resin composition containing (A) a polyamide having a viscosity number (as measured in the 96% sulfuric acid according to ISO 307 (1997)) of from 50 ml/g to 250 ml/g; (B) a polyphenylene ether; and (C) a phosphinate represented by a particular formula. The resin composition according to the present invention is excellent in flame retardancy, impact resistance and thin-wall moldability and can significantly suppress gas generation during the molding process and substantially inhibit the generation of deposits on a mold during injection molding. As a result, a molded product thereof excellent in surface appearance can be provided. | 2009-11-05 |
| 20090275683 | Flame Retardant Thermoplastic Resin Composition - Disclosed is a flame retardant thermoplastic resin composition that includes about 100 parts by weight of a mixed resin (A) including about 10 to about 90 wt % of an aromatic polyamide resin (A-1) and about 10 to about 90 wt % of a polyphenylene sulfide resin (A-2), about 0.5 to about 30 parts by weight of a phosphinic acid metal salt flame retardant (B), and about 10 to about 100 parts by weight of a filler (C). | 2009-11-05 |
| 20090275684 | HIGH CTI POLY(ARYLENE ETHER) COMPOSITION - Disclosed herein is a thermoplastic composition comprising: a poly(arylene ether); a poly(alkenyl aromatic) resin, an organophosphate ester flame retardant, and tricalcium phosphate. The composition may further comprise a reinforcing filler, black pigment, or combination thereof. | 2009-11-05 |
| 20090275685 | SELF-LUBRICATING SURFACE COATING COMPOSITION - A bearing having a surface and a self-lubricating surface coating composition deposited on the surface, wherein the self-lubricating surface coating composition includes a curable acrylate composition having a metallic composition. The metallic composition having a metallic acrylate compound according to Formula I: | 2009-11-05 |
| 20090275686 | PIGMENT AND POLYMERIC MATERIALS MATTED THEREWITH - A pigment, the production and use thereof, furthermore a polymeric material delustered with pigments, processes for producing this polymeric material, and the use thereof. | 2009-11-05 |
| 20090275687 | PROCESS OF RECYCLING PAINT SLUDGE AND COMPONENT MADE THEREOF - A process for making a solid component out of recycled paint sludge is provided. The process can include providing a paint sludge and providing a second material. Thereafter, the paint sludge and the second material are mixed to produce a paint sludge-second material mixture. The paint sludge-second material mixture is processed in order to produce a polymer containing precursor. The processing can include granulating or densifying the paint sludge-second material mixture. After the precursor has been produced, it can be placed within a molding machine and a solid component is molded. The molding machine can be an injection molding machine, an extrusion molding machine or a blow molding machine. | 2009-11-05 |
| 20090275688 | Thermoconductive Silicone Elastomer, Thermoconductive Silicone Elastomer Composition And Thermoconductive Medium - A thermoconductive silicone elastomer comprising a silicone elastomer being a cured body of a hydrosilation-curable organopolysiloxane composition, a reinforcement fine silica powder, a thermoconductive inorganic powder, and an alkylphenylpolysiloxane that is liquid at room temperature. A hydrosilation-curable thermoconductive silicone elastomer composition comprising: a hydrosilation-curable organopolysiloxane composition, a reinforcement fine silica powder, a thermoconductive inorganic powder, and an alkylphenylpolysiloxane that is liquid at room temperature. A thermoconductive medium comprising the aforementioned thermoconductive silicone elastomer. | 2009-11-05 |
| 20090275689 | ULTRASOUND ASSISTED CONTINUOUS PROCESS FOR DISPERSION OF NANOFIBERS AND NANOTUBES IN POLYMERS - The present invention relates to processes for producing high performance polymer composites via ultrasonic treatment after initial mixing. These high performance polymer composites made from a combination of polymer and nanofibers and/or nanotubes. The ultrasonic treating method of the disclosed allows a more highly dispersed polymer composite mixture which provides increased thermal, mechanical and electrical properties. | 2009-11-05 |
| 20090275690 | Articles Comprising Nonpolar Polyolefin and Polyurethane, and Methods for Their Preparation and Use - The adhesion between a low surface energy (i.e., nonpolar) material, e.g., a polyolefin such as polyethylene, and a high surface energy (i.e., polar) material, e.g., a polyester, polyurethane, polycarbonate or polylactic acid, is promoted by blending with the nonpolar material typically from 15 to less than 50 wt % of a diol-based thermoplastic polyurethane (d-TPU), e.g., a polydiene diol-based TPU, based on the combined weight of the nonpolar material and the d-TPU. The promoted adhesion allows for the effective painting, printing, over-molding or HF-welding of a nonpolar substrate, e.g., a polyolefin film, with a polar coating, e.g., a paint, ink, etc. Aqueous dispersions can also be made from the blend of nonpolar material and d-TPU. | 2009-11-05 |
| 20090275691 | METHOD FOR THE PRODUCTION OF CO-EXTRUDATES COMPOSED OF POLYSTYRENE AND OF A CROSSLINKED POLYVINYLPYRROLIDONE WITH REDUCED RESIDUAL STYRENE MONOMER CONTENT - A method for removing residual styrene monomers from co-extrudates comprising polystyrene and water-insoluble, crosslinked polyvinylpyrrolidone, which comprises subjecting an aqueous suspension of the particulate solid co-extrudate to a heat treatment at temperatures of 60 to 99° C., the weight ratio of solid co-extrudate to water in the suspension being 1:1.5 to 1:20, and the concentration of the suspension being kept constant during the treatment. | 2009-11-05 |
| 20090275692 | Alphatic polyester composition and method for producing the same - Polyglycolic acid and polylactic acid having a weight-average molecular weight of at most 50,000 are melt-kneaded in the presence of a thermal stabilizer to obtain a polyglycolic acid-based aliphatic polyester composition. The aliphatic polyester composition alleviates the too fast crystallizability of polyglycolic acid which has been problematic in forming or molding of polyglycolic acid alone or in combination with another thermoplastic resin, thus showing a crystallization speed which has been lowered and can be controlled in a wide range. | 2009-11-05 |
| 20090275693 | Viscosity Control for Reduced Fluorosurfactant Aqueous Fluoropolymer Dispersions by the Addition of Cationic Surfactants - A stabilized aqueous fluoropolymer dispersion comprising fluoropolymer particles, wherein the dispersion contains less that about 300 ppm fluorosurfactant based on the weight of the dispersion and a cationic surfactant. The cationic surfactant aids in reducing the viscosity of the dispersion and preferred cationic surfactants are volatile in coating or film casting operations involving drying and sintering of the dispersion. | 2009-11-05 |
| 20090275694 | Spin-on-Glass Anti-Reflective Coatings for Photolithography - The present invention provides a siloxane polymer family comprising siloxane polymer made from: (a) a strongly absorbing compound; (b) at least one silane having good leaving groups; and (c) at least one silane having good leaving groups that is different than (b); wherein the siloxane polymer family exhibits a relationship that is concave/convex or is located in the region enclosed by a concave/convex relationship for the ratio of (a) to (b) to (c) and the siloxane polymer's extinction coefficient k value. These siloxane polymers are preferably used as spin-on glass compositions for films in the microelectronics applications. | 2009-11-05 |
| 20090275695 | PROCESS FOR PREPARING SILOXANE-BASED COMPOSITIONS AND DERIVATIVE COMPOSITIONS THEREOF - A process for forming a new group of siloxane-based compositions by a one-step co-hydrolysis and the compositions formed thereof. The siloxane-based compositions being functionalized with a carbon-carbon double (C═C) bond and a silicon-hydrogen (Si—H) bond. The C═C bond and hydrogen (H) each being attached directly to a silicon (Si) atom of the silicon-oxygen (Si—O) backbone of the siloxane-based composition. The C═C bond may be from a vinyl or an aromatic radical like a phenyl substituent. The C═C bond substituent provides the functionality needed for forming crosslinkages through standard dehydrocoupling catalysts without the need for siloxane fluids or organic compounds containing alkyl or aryl functional groups. The process provides for varying proportions of silanes as starting monomers to tailor the desired silicon, carbon, hydrogen and oxygen ratios in the siloxane-based compositions or resins. The siloxane-based compositions may be used as precursors or replacement resins in the fabrication of other materials. | 2009-11-05 |
| 20090275696 | Vapor Grown Carbon Fiber, and Production Method and Use Thereof - A producing method of a carbon fiber by spraying a raw material solution containing a carbon source and a transition metallic compound into a reaction zone and subjecting the raw material solution to thermal decomposition, which is characterized in (1) spraying the raw material solution at a spray angle of 3° to 30° and (2) feeding a carrier gas through at least one site other than an inlet through which the raw material solution is sprayed. A composite material comprising a vapor grown carbon fiber, each fiber filament of the carbon fiber having a branching degree of at least 0.15 occurrences/μm and a bulk density of 0.025 g/cm | 2009-11-05 |
| 20090275697 | Manufacturing process for liquid crystalline polymer - The properties of a liquid crystalline polymer (LCP) containing ester linkages and made in the presence of an excess of diol are improved by treating the LCP with a dicarboxylic acid at elevated temperature. The resulting LCPs are useful as molding resins and for films. | 2009-11-05 |
| 20090275698 | Method of Making Polybutylene Terephthalate and Compositions and Articles Comprising the Same - A process for making modified polybutylene terephthalate random copolymers from a polyethylene terephthalate component includes reacting an oligomeric diol component selected from the group consisting of bis(hydroxybutyl)terephthalate, bis(hydroxybutyl)isophthalate, hydroxybutyl-hydroxyethyl terephthalate, and combinations thereof to a reactor; (i) a polyethylene terephthalate component selected from the group consisting of polyethylene terephthalate and polyethylene terephthalate copolymers with (ii) a diol component selected from the group consisting of 1,4-butanediol, ethylene glycol, propylene glycol, and combinations thereof, in the reactor under conditions sufficient to depolymerize the polyethylene terephthalate component into a first molten mixture; combining the first molten mixture is combined with 1,4-butanediol under conditions to form a second molten mixture; and placing the second molten mixture under conditions sufficient to produce the modified polybutylene terephthalate random copolymers. Also described are compositions and articles made from the process. | 2009-11-05 |
| 20090275699 | Starch containing formaldehyde-free thermoset binders for fiber products - Binder compositions are described that include a carboxyl-containing polymer, a cross-linking agent, and a starch compound having a molecular weight greater than about 10,000 g/mol. In addition, fiber products are described that include mineral or polymeric fibers and a binder prepared from an aqueous composition that includes a carboxyl-containing polymer, a cross-linking agent, and a starch having a molecular weight greater than 10,000 g/mol. | 2009-11-05 |
| 20090275700 | Propylene-Based Polymer Composition for Adhesive Use and Laminate Thereof - A propylene-based polymer composition for adhesive use and a laminate structure thereof are provided, wherein decrease of bonding strength is prevented when the laminate structure is formed and heat treatment is applied and whitening in bending process is suppressed. | 2009-11-05 |
| 20090275701 | Curable Composition Based On Polyurethane And On Block Copolymers, And Transparent Material Obtained From Said Composition - Curable composition comprising: (a) one or more particular polyisocyanates or a polyurethane prepolymer obtained by the polycondensation of a polyisocyanate in excess, chosen from said polyisocyanates, with one or more polyols comprising at least two free alcohol functional groups, chosen from polypropoxylated or polyethoxylated bisphenol A compounds and polyfunctional polycaprolactone-alcohols; (b) one or more polyols comprising at least two free alcohol functional groups, chosen from polypropoxylated or polyethoxylated bisphenol A compounds and polyfunctional polycaprolactone-alcohols, and polyurethane prepolymers obtained by the polycondensation of one or more polyols in excess, chosen from the above polyols, with one or more particular polyisocyanates, the ratio of the number of isocyanate functional groups of the polyisocyanate component (a) to the number of alcohol functional groups of the polyol component (b) being between 1.00 and 1.20; and (c) 5% to 80% by weight, relative to the total weight of (a), (b) and (c), of one or more polystyrene-block-polybutadiene-block-poly(methyl methacrylate) block copolymers; | 2009-11-05 |
| 20090275702 | MOISTURE CURABLE POLYMER HAVING SiF GROUP, AND CURABLE COMPOSITION CONTAINING THE SAME - A moisture curable polymer and a curable composition having superior curability are provided. A polymer having a silicon group represented by the general formula: —SiF | 2009-11-05 |
